Morgan Stanley analyst Erin Wright raised the firm’s price target on BrightSpring Health (BTSG) to $40 from $32 and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services Shines in Q3 Earnings Call
- BrightSpring Health price target raised to $38 from $32 at Mizuho
- BrightSpring Health price target raised to $41 from $30 at BTIG
- BrightSpring Health price target raised to $42 from $35 at UBS
- BrightSpring Health Services, Inc.: Strong Financial Performance and Growth Prospects Justify Buy Rating